Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply
Aliment Pharmacol Ther
.
2020 Nov;52(10):1621.
doi: 10.1111/apt.16113.
Authors
Thomas P Chapman
1
2
,
Catarina Frias Gomes
3
,
Edouard Louis
4
,
Jean-Frédéric Colombel
5
,
Jack Satsangi
1
Affiliations
1
Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, UK.
2
Department of Gastroenterology, Western Sussex Hospitals NHS Foundation Trust, Worthing, UK.
3
Surgical Department, Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal.
4
Department of Gastroenterology, CHU Liège University Hospital, Liège, Belgium.
5
The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
PMID:
33085981
DOI:
10.1111/apt.16113
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Inflammatory Bowel Diseases* / drug therapy
Mesalamine*
Substances
Mesalamine